Sangamo BioSciences | SGMO - Cost Of Sales


Sangamo BioSciences reported 2.42M in Cost of Sales for its fiscal quarter ending in June of 2024.





Cost Of Sales Change Date
Alaunos Therapeutics USD 0 18K Sep/2024
Alnylam Pharmaceuticals USD 211.12M 56.6M Mar/2026
Amgen USD 1.6B 187M Mar/2026
Bayer EUR 5.23B 731M Mar/2026
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Biogen USD 797.5M 302M Mar/2026
BioMarin Pharmaceutical USD 199.48M 37.93M Mar/2026
Cipla INR 26.32B 2.79B Mar/2026
Clal Biotechnology ILS 16.49M 2.64M Jun/2022
Compugen USD 1.82M 1.71M Mar/2026
CSL USD 3.87B 2.08B Dec/2025
Gilead Sciences USD 1.44B 174M Mar/2026
GlaxoSmithKline GBP 1.88B 736M Mar/2026
Grifols EUR 1.51B 184.45M Dec/2025
Ionis Pharmaceuticals USD 3M 5M Mar/2026
J&J USD 8.07B 103M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Merck USD 2.94B 380M Mar/2026
Novartis USD 3.46B 83M Mar/2026
Omeros USD 33.16M 18.52M Jun/2024
Pfizer USD 4.59B 1.7B Mar/2026
Roche Holding CHF 8.48B 4.61B Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 3.67B 621M Mar/2026
Sarepta Therapeutics USD 109.46M 289.93M Mar/2026
Ultragenyx Pharmaceutical USD 30M 1000K Mar/2026
Vertex Pharmaceuticals USD 392.8M 73.2M Mar/2026